Core Viewpoint - Pharming Group N.V. has received a positive opinion from the CHMP of the EMA recommending marketing authorization for Joenja® (leniolisib) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 years and older, marking a significant advancement in APDS care in Europe [1][3][6]. Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare and life-threatening diseases, headquartered in Leiden, the Netherlands [10]. Product Information - Joenja® (leniolisib) is an oral small molecule PI3Kδ inhibitor, currently approved in the U.S., U.K., Australia, and Israel for patients aged 12 years and older with APDS, and in Japan for patients aged 4 years and older [8][4]. - The positive CHMP opinion is based on a Phase II/III clinical trial involving 31 patients, demonstrating a statistically significant impact on immune dysregulation and immunodeficiency [3][6]. Market Potential - If approved by the European Commission, Joenja would be the first treatment for APDS in the European Union, with centralized marketing authorization valid across all 27 EU Member States, Norway, Iceland, and Liechtenstein [2][6]. Clinical Insights - The clinical program for leniolisib has shown meaningful improvements in immune dysregulation and deficiency, suggesting it could significantly change the clinical outlook for patients with APDS [4][3]. - APDS affects approximately 1 to 2 individuals per million worldwide, and patients often experience a median diagnostic delay of 7 years [7][5].

Core Viewpoint - Pharming Group N.V. has received approval from Japan's Ministry of Health, Labour and Welfare for Joenja® (leniolisib), marking it as the first treatment for activated PI3K delta syndrome (APDS) in Japan and globally for children aged 4 to 11 [1][2][7] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare and life-threatening diseases, headquartered in Leiden, the Netherlands [11] Product Details - Joenja® (leniolisib) is an oral, selective PI3K delta inhibitor approved for patients aged 4 years and older, targeting APDS, a rare primary immunodeficiency [1][9] - The approval is based on positive Phase III clinical trial data demonstrating significant improvements in immune function and tolerability [4][9] Market and Distribution - OrphanPacific, Inc. will act as the Marketing Authorization Holder for Joenja in Japan, collaborating with Pharming for supply and distribution [2] - The launch of Joenja is contingent upon agreement with the MHLW regarding its National Health Insurance drug price [2] Clinical Significance - The approval of Joenja is a significant advancement for the APDS community in Japan, providing the first targeted treatment option for this rare disease [3][4] - The clinical trials included a global, randomized, placebo-controlled study and a Japanese open-label study, both showing improvements in lymphadenopathy and B cell function [4][5] Regulatory Pathway - The application for Joenja was evaluated under the Priority Review pathway after receiving Orphan Drug Designation from the MHLW in May 2023 [5]

Core Insights - Pharming Group N.V. reported a strong financial performance for 2025, with total revenues increasing by 27% to US$376.1 million, driven by growth in RUCONEST® and Joenja® [2][7][35] - The company achieved an operating profit of US$25.8 million in 2025, a significant improvement from a loss of US$8.6 million in 2024 [4][40] - Pharming anticipates total revenues for 2026 to be between US$405 million and US$425 million, representing growth of 8% to 13% [4][56] Financial Performance - Total revenues for Q4 2025 increased by 15% to US$106.5 million compared to Q4 2024 [29] - RUCONEST® revenues for the full year 2025 reached US$317.9 million, a 26% increase year-over-year, while Joenja® revenues increased by 29% to US$58.2 million [8][36] - The company reported a net profit of US$2.5 million for 2025, compared to a net loss of US$11.8 million in 2024 [43] Product Performance - RUCONEST® continues to be a key treatment option for patients with HAE, with a 9% revenue increase in Q4 2025 [8][9] - Joenja® saw a 53% revenue increase in Q4 2025, driven by a significant rise in patients on paid therapy in the U.S. [10][11] - The U.S. market accounted for 86% of Pharming's total revenues in 2025, highlighting the importance of this market for the company's growth [11] Pipeline and Future Outlook - Pharming's pipeline includes key upcoming milestones, such as Phase II readouts for leniolisib in broader primary immunodeficiencies expected in the second half of 2026 [6][21] - The company is on track to complete enrollment in the pivotal FALCON study for napazimone (KL1333) in 2026, with data readout anticipated in late 2027 [6][24] - Pharming aims to enhance capital allocation to drive growth and is focused on potential acquisitions and in-licensing opportunities in rare diseases [56]

Core Viewpoint - Pharming Group N.V. is under investigation for potential securities fraud and unlawful business practices following a negative response from the FDA regarding its drug application for Joenja® [1][3] Group 1: FDA Response - On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter (CRL) for its supplemental New Drug Application (sNDA) for Joenja® [3] - The FDA raised concerns about potential underexposure in lower weight pediatric patients and requested additional pharmacokinetic data to reassess proposed pediatric doses [3] - The letter also highlighted issues with one of the analytical methods used for production batch testing, requiring further data and clarification [3] Group 2: Market Reaction - Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price dropped by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026 [3]

Core Viewpoint - Pharming Group N.V. is under investigation for potential securities fraud following the FDA's Complete Response Letter regarding its drug Joenja® [1][2] Group 1: Company Overview - Pharming Group N.V. is a biopharmaceutical company focused on developing innovative therapies for rare diseases [2] - The company’s stock, represented by American Depositary Receipts (ADRs), experienced a significant decline of 17.07% following negative FDA news [2] Group 2: FDA Response - On February 1, 2026, the FDA issued a Complete Response Letter for Pharming's supplemental New Drug Application for Joenja® [2] - The FDA raised concerns about potential underexposure in lower weight pediatric patients and requested additional pharmacokinetic data [2] - An issue was also identified with one of the analytical methods used for production batch testing, necessitating further data and clarification [2] Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Pharming investors regarding possible securities fraud or unlawful business practices by the company and its officers [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3]

Core Viewpoint - Pharming Group announced that the FDA issued a Complete Response Letter (CRL) for its supplemental New Drug Application (sNDA) for Joenja® (leniolisib) as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS) [1][5] Regulatory Update - The FDA raised concerns about potential underexposure in lower weight pediatric patients and requested additional pharmacokinetic data to reassess proposed doses [2] - An issue was identified with one of the analytical methods used for production batch testing, prompting the FDA to request further data and clarification [2] - Pharming plans to address the issues outlined in the CRL and intends to request a Type A meeting with the FDA to discuss next steps for resubmission [3] Clinical Data - The sNDA submission was based on positive results from a Phase III study showing improvements in lymphadenopathy and naïve B cells over 12 weeks, indicating a correction of the immune defect in children [4] - Safety data from 8 months of treatment indicated that all treatment-emergent adverse events were mild to moderate, with no serious drug-related adverse events reported [4] Market Context - Currently, there are no approved treatments for children with APDS under the age of 12 globally, highlighting the significance of Joenja's potential impact [5] - Joenja received FDA approval for treating APDS in patients aged 12 years and older in March 2023, which remains unaffected by the recent regulatory action [3][5] Disease Overview - APDS is a rare primary immunodeficiency characterized by severe recurrent infections and immune dysregulation, affecting approximately 1 to 2 people per million worldwide [6] - The condition is caused by variants in the PIK3CD or PIK3R1 genes, leading to hyperactivity of the PI3Kδ pathway, which impairs immune cell function [6] Product Information - Leniolisib is an oral PI3Kδ inhibitor approved in several countries as the first targeted treatment for APDS in patients aged 12 years and older [7] - The drug is currently under regulatory review in multiple regions and is being evaluated in clinical trials for other primary immunodeficiencies [8]

Core Insights - Pharming Group N.V. reported a strong financial performance for Q3 2025, with total revenues increasing by 30% to US$97.3 million compared to Q3 2024, driven by growth in both RUCONEST® and Joenja® [9][30][31] Financial Performance - Total revenues for Q3 2025 reached US$97.3 million, a 30% increase from US$74.8 million in Q3 2024 [30] - RUCONEST® revenue increased by 29% to US$82.2 million, reflecting sustained growth in patients and prescribers [9][10] - Joenja® revenue grew by 35% to US$15.1 million, driven by a significant increase in patients on paid therapy [13][31] - Operating profit surged by 285% to US$15.8 million compared to US$4.1 million in Q3 2024 [32] - The company generated US$32 million in cash flow from operations during the quarter [34] Strategic Developments - Pharming announced a significant reduction in general and administrative headcount to optimize capital deployment towards high-growth initiatives [5][23] - The company is focusing on expanding its pipeline, particularly for leniolisib in broader primary immunodeficiency populations and addressing unmet needs in primary mitochondrial disease with KL1333 [4][5] Market Position and Outlook - The company raised its full-year revenue guidance to between US$365 million and US$375 million, up from the previous range of US$335 million to US$350 million [6][44] - The U.S. market contributed 89% of Q3 revenue, while the EU and Rest of World contributed 11% [14] - Pharming plans to launch a pediatric formulation of leniolisib for children aged 4 to 11 years, with FDA priority review expected by January 2026 [20][44] Organizational Changes - Leverne Marsh has been appointed as Chief Commercial Officer, effective January 1, 2026, succeeding Stephen Toor [7][24] - Kenneth Lynard was appointed as Chief Financial Officer, effective October 1, 2025, enhancing the company's financial leadership [22] Corporate Highlights - Pharming was promoted from the Euronext AScX® to the AMX® index, reflecting its growing market capitalization and trading activity [25] - The company is working on options to mitigate the impact of recently announced U.S. tariffs, although it does not expect a material impact on its business [26]

Core Insights - Pharming Group N.V. announced that 12 abstracts have been accepted for presentation at the ACAAI 2025 Annual Scientific Meeting, highlighting the company's commitment to advancing research in hereditary angioedema (HAE) and activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) [1][3]. Summary by Category Clinical Data - Five posters will present positive clinical, economic, and comparative data for RUCONEST® in the treatment of on-demand hereditary angioedema (HAE) [2]. - Seven posters will focus on the real-world effectiveness of Joenja® (leniolisib), including results from the Phase III pediatric trial and insights into the burden faced by pediatric patients and caregivers dealing with APDS [2]. Presentation Details - Specific studies include an indirect treatment comparison of recombinant C1 inhibitor and Sebetralstat for HAE on-demand therapy, cost-effectiveness analysis, and patient-reported outcome measures across clinical trials [4][5]. - The presentations are scheduled for various dates and times during the ACAAI meeting, with ePosters accessible online for registered attendees [5]. Company Overview - Pharming Group is a biopharmaceutical company focused on developing innovative medicines for rare diseases, with a significant presence in both the U.S. and Europe [14].

Core Insights - Pharming Group N.V. reported a strong second quarter with a total revenue growth of 26% and positive operating profit, driven by significant growth in RUCONEST® and Joenja® [2][7][29] - The company raised its full-year revenue guidance to between US$335 million and US$350 million, up from the previous range of US$325 million to US$340 million [7][44] Financial Performance - Total revenues for Q2 2025 increased by 26% to US$93.2 million compared to Q2 2024, with RUCONEST® revenue growing by 28% to US$80.4 million and Joenja® revenue increasing by 15% to US$12.8 million [7][29][30] - Operating profit for Q2 2025 was US$10.8 million, a significant improvement from a loss of US$3.1 million in Q2 2024 [7][31] - For the first half of 2025, total revenues rose by 33% to US$172.3 million, with RUCONEST® revenues up 37% to US$149.0 million [35][36] Product Development and Market Expansion - Joenja® is showing accelerated uptake, with patient growth in the first half of 2025 surpassing the total for all of 2024 [2][11] - A recent study published in the journal Cell suggests that the prevalence of APDS may be up to 100 times higher than previously estimated, potentially expanding Joenja®'s addressable patient population [3][16] - The company launched Joenja® in the U.K. and submitted a regulatory filing for leniolisib in Japan, indicating ongoing efforts to expand market access [4][20] Strategic Initiatives - Pharming is working on mitigating the impact of U.S. tariffs, although it does not expect a material impact on its business [5] - The company is on track to reduce general and administrative expenses by 15% or US$10 million to optimize capital allocation for sustainable growth [26] - The acquisition of Abliva AB was completed, increasing Pharming's ownership to 100% [25] Cash Flow and Financial Position - Cash and marketable securities increased to US$130.8 million at the end of Q2 2025, up from US$108.9 million at the end of Q1 2025, primarily due to cash generated from operations [7][34] - The company reported a net profit of US$4.6 million for Q2 2025, compared to a net loss of US$1.2 million in Q2 2024 [33]

Core Insights - Pharming Group N.V. reported a strong performance in the first quarter of 2025, with total revenues increasing by 42% to US$79.1 million compared to the same period in 2024, driven primarily by a 49% increase in RUCONEST® revenue [6][33][37] - The company has raised its full-year revenue guidance to between US$325 million and US$340 million, reflecting confidence in continued growth [2][37] - Pharming is making significant progress in expanding the availability of Joenja® for additional patients and is preparing for regulatory submissions in multiple markets [3][12][18] Financial Performance - Total revenues for Q1 2025 were US$79.1 million, up from US$55.6 million in Q1 2024, with RUCONEST® contributing US$68.6 million, a 49% increase [6][33] - Joenja® revenues reached US$10.5 million, a 9% increase compared to Q1 2024, with an 18% increase in unit sales volume [6][9][33] - Operating loss improved to US$7.0 million from US$16.3 million in Q1 2024, with adjusted operating profit of US$0.8 million when excluding non-recurring expenses related to the Abliva acquisition [35][36] Product Developments - Joenja® was launched in England and Wales in April 2025 following a positive reimbursement decision from NICE, and the company is preparing to file for U.S. FDA approval for pediatric use in Q3 2025 [3][12][17] - The company is advancing its pipeline, including ongoing clinical trials for leniolisib in primary immunodeficiencies and KL1333 for mitochondrial diseases [4][21][25] Market Contributions - The U.S. market accounted for 97% of total revenues in Q1 2025, highlighting the strong demand for RUCONEST® and Joenja® in this region [7][8] - The company has identified approximately 250 APDS patients in the U.S. eligible for Joenja®, with ongoing efforts to find and transition more patients to paid therapy [11][13][14] Strategic Initiatives - Pharming completed the acquisition of Abliva AB for approximately US$66.1 million, which is expected to enhance future growth prospects [23][24] - The company is optimizing capital allocation with a target of reducing general and administrative expenses by 15% or US$10 million annually [2][6]